AAP
LXEO icon

Arax Advisory Partners’s Lexeo Therapeutics LXEO Stock Holding History

Arax Advisory Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
+3,409
New +$18.4K ﹤0.01% 4098
2025
Q4 		– Sell
-4,551
Closed -$30.2K – 4346
2025
Q3 		$30.2K Buy
+4,551
New +$22K ﹤0.01% 2080
2024
Q4 		– Sell
-12
Closed -$109 – 2607
2024
Q3 		$109 Hold
12
– – ﹤0.01% 2556
2024
Q2 		$193 Buy
+12
New +$174 ﹤0.01% 2444

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Arax Advisory Partners's LXEO Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Lexeo Therapeutics (LXEO) in Q2 2026: 3,409 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #4098 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in LXEO as recently as Q3 2025.

Arax Advisory Partners first reported a position in LXEO in Q2 2024 and has held it in 4 quarters since. The position peaked at $30.2K in Q3 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Arax Advisory Partners held 3,409 shares of Lexeo Therapeutics worth $15.9K as of Q2 2026.
  • Lexeo Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Lexeo Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4098 holding.
  • Arax Advisory Partners first reported a position in Lexeo Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • Arax Advisory Partners's Lexeo Therapeutics position peaked at $30.2K in Q3 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.